{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["54(4)"],"submitter":["Jeong SH"],"funding":["Consortium for Improving Survival of Lymphoma"],"pubmed_abstract":["<h4>Purpose</h4>Febrile neutropenia (FN) can cause suboptimal treatment and treatment-related mortality (TRM) in diffuse large B-cell lymphoma (DLBCL) patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP).<h4>Materials and methods</h4>We conducted a prospective cohort study to evaluate the effectiveness of pegfilgrastim prophylaxis in DLBCL patients receiving R-CHOP, and we compared them with the PROCESS cohort (n=485).<h4>Results</h4>Since January 2015, 986 patients with DLBCL were enrolled. Pegfilgrastim was administered at least once in 930 patients (94.3%), covering 90.3% of all cycles. FN developed in 137 patients (13.9%) in this cohort (23.7% in the PROCESS cohort, p<0.001), and 4.2% of all cycles (10.2% in the PROCESS cohort, p<0.001)"],"journal":["Cancer research and treatment"],"pagination":["1268-1277"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9582490"],"repository":["biostudies-literature"],"pubmed_title":["Pegfilgrastim Prophylaxis Is Effective in the Prevention of Febrile Neutropenia and Reduces Mortality in Patients Aged ≥ 75 Years with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Prospective Cohort Study."],"pmcid":["PMC9582490"],"pubmed_authors":["Yi SY","Kwon JH","Suh C","Koh Y","Lee GW","Yoo KH","Jo JC","Lee HS","Park Y","Kim SH","Sohn BS","Kim WS","Kim MK","Kim SJ","Do YR","Shin HJ","Hyun SY","Eom HS","Oh SY","Kang HJ","Park BB","Kim HJ","Yoon DH","Won JH","Yang DH","Yun HJ","Kwak JY","Yi JH","Jeong SH","Lee WS","Choi YS"],"additional_accession":[]},"is_claimable":false,"name":"Pegfilgrastim Prophylaxis Is Effective in the Prevention of Febrile Neutropenia and Reduces Mortality in Patients Aged ≥ 75 Years with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Prospective Cohort Study.","description":"<h4>Purpose</h4>Febrile neutropenia (FN) can cause suboptimal treatment and treatment-related mortality (TRM) in diffuse large B-cell lymphoma (DLBCL) patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP).<h4>Materials and methods</h4>We conducted a prospective cohort study to evaluate the effectiveness of pegfilgrastim prophylaxis in DLBCL patients receiving R-CHOP, and we compared them with the PROCESS cohort (n=485).<h4>Results</h4>Since January 2015, 986 patients with DLBCL were enrolled. Pegfilgrastim was administered at least once in 930 patients (94.3%), covering 90.3% of all cycles. FN developed in 137 patients (13.9%) in this cohort (23.7% in the PROCESS cohort, p<0.001), and 4.2% of all cycles (10.2% in the PROCESS cohort, p<0.001)","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Oct","modification":"2026-05-28T03:25:40.969Z","creation":"2025-04-04T23:37:11.035Z"},"accession":"S-EPMC9582490","cross_references":{"pubmed":["34990525"],"doi":["10.4143/crt.2021.1168"]}}